GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (LTS:0GP7) » Definitions » E10

Medivir AB (LTS:0GP7) E10 : kr0.62 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is Medivir AB E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Medivir AB's adjusted earnings per share data for the three months ended in Mar. 2024 was kr-0.230. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is kr0.62 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Medivir AB's average E10 Growth Rate was -51.70% per year. During the past 3 years, the average E10 Growth Rate was 4.10% per year. During the past 5 years, the average E10 Growth Rate was 10.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Medivir AB was 13.70% per year. The lowest was 2.70% per year. And the median was 4.10% per year.

As of today (2024-06-10), Medivir AB's current stock price is kr2.92669. Medivir AB's E10 for the quarter that ended in Mar. 2024 was kr0.62. Medivir AB's Shiller PE Ratio of today is 4.72.

During the past 13 years, the highest Shiller PE Ratio of Medivir AB was 52.57. The lowest was 1.82. And the median was 7.75.


Medivir AB E10 Historical Data

The historical data trend for Medivir AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB E10 Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.45 1.84 0.94 1.41 1.99

Medivir AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 1.78 1.80 1.99 0.62

Competitive Comparison of Medivir AB's E10

For the Biotechnology subindustry, Medivir AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medivir AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medivir AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Medivir AB's Shiller PE Ratio falls into.



Medivir AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Medivir AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.23/132.2054*132.2054
=-0.230

Current CPI (Mar. 2024) = 132.2054.

Medivir AB Quarterly Data

per share eps CPI Adj_EPS
201406 12.903 100.432 16.985
201409 7.958 100.161 10.504
201412 3.155 100.225 4.162
201503 1.527 99.950 2.020
201506 1.473 99.995 1.947
201509 -0.242 100.228 -0.319
201512 -1.043 100.276 -1.375
201603 -1.009 100.751 -1.324
201606 -0.996 101.019 -1.303
201609 -1.258 101.138 -1.644
201612 10.306 102.022 13.355
201703 -2.415 102.022 -3.129
201706 -2.630 102.752 -3.384
201709 -2.650 103.279 -3.392
201712 -3.350 103.793 -4.267
201803 -2.132 103.962 -2.711
201806 -2.536 104.875 -3.197
201809 -1.971 105.679 -2.466
201812 -3.189 105.912 -3.981
201903 -1.547 105.886 -1.932
201906 -0.343 106.742 -0.425
201909 -0.639 107.214 -0.788
201912 -0.888 107.766 -1.089
202003 -0.787 106.563 -0.976
202006 -0.426 107.498 -0.524
202009 0.156 107.635 0.192
202012 -0.308 108.296 -0.376
202103 -0.147 108.360 -0.179
202106 -0.254 108.928 -0.308
202109 -0.197 110.338 -0.236
202112 -0.369 112.486 -0.434
202203 -0.483 114.825 -0.556
202206 -0.344 118.384 -0.384
202209 -0.221 122.296 -0.239
202212 -0.550 126.365 -0.575
202303 -0.340 127.042 -0.354
202306 -0.385 129.407 -0.393
202309 -0.344 130.224 -0.349
202312 -0.472 131.912 -0.473
202403 -0.230 132.205 -0.230

Add all the adjusted EPS together and divide 10 will get our e10.


Medivir AB  (LTS:0GP7) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Medivir AB's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=2.92669/0.62
=4.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Medivir AB was 52.57. The lowest was 1.82. And the median was 7.75.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Medivir AB E10 Related Terms

Thank you for viewing the detailed overview of Medivir AB's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Medivir AB (LTS:0GP7) Business Description

Traded in Other Exchanges
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.

Medivir AB (LTS:0GP7) Headlines

No Headlines